Loading...
XSHE
002252
Market cap4.46bUSD
Jul 10, Last price  
4.58CNY
1D
2.23%
1Q
-20.21%
Jan 2017
-80.16%
IPO
-26.48%
Name

Shanghai RAAS Blood Products Co Ltd

Chart & Performance

D1W1MN
XSHE:002252 chart
P/E
19.15
P/S
4.11
EPS
0.24
Div Yield, %
0.72%
Shrs. gr., 5y
-0.51%
Rev. gr., 5y
21.62%
Revenues
7.35b
-10.13%
278,689,993309,976,913309,860,472387,519,941483,357,124567,385,772662,676,897496,359,5581,319,735,2292,013,321,6282,326,250,3481,927,748,4251,804,235,3992,584,983,9822,761,682,0354,287,726,7486,567,198,5807,963,958,5668,176,460,0477,348,183,032
Net income
1.58b
-28.10%
50,711,18081,769,205104,790,807135,663,016185,498,269200,354,617225,013,846143,794,620510,854,9411,442,414,3051,613,153,635835,828,594-1,518,397,015607,893,7171,323,711,0611,294,510,0521,880,090,0711,779,476,9352,193,293,3741,577,013,866
CFO
-105m
L-78.24%
53,584,846175,710,568107,642,052116,011,121200,209,539178,028,545263,464,688-90,108,071465,961,164762,420,968638,223,427268,758,822262,500,811872,694,4701,168,847,1461,294,013,2191,725,596,0632,277,884,080-482,055,042-104,891,803
Dividend
Jul 14, 20250.033 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, production, and sale of blood products. It provides human albumin, intravenous injection of human immunoglobulin, coagulation factor products, vaccines, diagnostic reagents, and testing services. The company was founded by Kieu Hoang on October 29, 1988 and is headquartered in Shanghai, China.
IPO date
Jun 23, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT